[go: up one dir, main page]

WO2006045319A3 - Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique - Google Patents

Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique Download PDF

Info

Publication number
WO2006045319A3
WO2006045319A3 PCT/DK2005/000694 DK2005000694W WO2006045319A3 WO 2006045319 A3 WO2006045319 A3 WO 2006045319A3 DK 2005000694 W DK2005000694 W DK 2005000694W WO 2006045319 A3 WO2006045319 A3 WO 2006045319A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
renal
liver failure
growth hormone
individuals suffering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2005/000694
Other languages
English (en)
Other versions
WO2006045319A2 (fr
Inventor
Birgitte Holst Lange
Hans T Schambye
Tina Geritz Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gastrotech Pharma AS
Original Assignee
Gastrotech Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gastrotech Pharma AS filed Critical Gastrotech Pharma AS
Priority to EP05796707A priority Critical patent/EP1812044A2/fr
Publication of WO2006045319A2 publication Critical patent/WO2006045319A2/fr
Publication of WO2006045319A3 publication Critical patent/WO2006045319A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Utilisation d'un composé sécrétagogue pour la préparation d'un médicament destiné à traiter un individu souffrant d'une insuffisance rénale et/ou hépatique. Procédé de stimulation de l'appétit, de l'ingestion d'aliments et/ou du gain de poids chez un individu souffrant d'une insuffisance hépatique et/ou rénale, le procédé consistant à administrer un sécrétagogue audit patient.
PCT/DK2005/000694 2004-10-27 2005-10-27 Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique Ceased WO2006045319A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05796707A EP1812044A2 (fr) 2004-10-27 2005-10-27 Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200401655 2004-10-27
DKPA200401654 2004-10-27
DKPA200401654 2004-10-27
DKPA200401655 2004-10-27

Publications (2)

Publication Number Publication Date
WO2006045319A2 WO2006045319A2 (fr) 2006-05-04
WO2006045319A3 true WO2006045319A3 (fr) 2006-09-28

Family

ID=36101732

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2005/000694 Ceased WO2006045319A2 (fr) 2004-10-27 2005-10-27 Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique

Country Status (2)

Country Link
EP (1) EP1812044A2 (fr)
WO (1) WO2006045319A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851448B2 (en) 2004-11-24 2010-12-14 Neopro Labs, Llc Methods for modulating activities in plants
US8217141B2 (en) 2007-05-17 2012-07-10 Neopro Labs, Llc Crystalline and amorphous forms of peptide

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
WO2007112453A2 (fr) 2006-03-28 2007-10-04 Neopro Labs, Llc Méthodes et compositions pour traiter des conditions
US9371297B2 (en) 2007-02-09 2016-06-21 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
US20100168033A1 (en) * 2007-05-31 2010-07-01 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
US8476408B2 (en) 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
US8399643B2 (en) 2009-02-26 2013-03-19 Transposagen Biopharmaceuticals, Inc. Nucleic acids encoding hyperactive PiggyBac transposases
EP2790721B8 (fr) 2011-12-15 2018-11-28 Millendo Therapeutics SAS Fragments de ghréline non acylée pour l'utilisation dans le traitement du syndrome de prader-willi
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
WO2024177909A1 (fr) * 2023-02-21 2024-08-29 Endevica Bio, Inc. Procédés de stimulation de l'appétit et/ou d'augmentation du poids corporel chez des patients ayant une maladie fibrotique à l'aide d'analogues de mélanocortine d'origine non naturelle

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056592A1 (fr) * 2000-02-01 2001-08-09 Novo Nordisk A/S Utilisation de composes pour la regulation de l'absorption de nourriture
WO2001092292A2 (fr) * 2000-05-30 2001-12-06 Merck & Co., Inc. Analogues de la ghreline
EP1197496A1 (fr) * 1999-07-23 2002-04-17 Kenji Kangawa Nouveaux peptides
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
WO2005014032A2 (fr) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Utilisations de secretagogues

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111461A1 (en) * 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
EP1197496A1 (fr) * 1999-07-23 2002-04-17 Kenji Kangawa Nouveaux peptides
WO2001056592A1 (fr) * 2000-02-01 2001-08-09 Novo Nordisk A/S Utilisation de composes pour la regulation de l'absorption de nourriture
WO2001092292A2 (fr) * 2000-05-30 2001-12-06 Merck & Co., Inc. Analogues de la ghreline
WO2005014032A2 (fr) * 2003-08-06 2005-02-17 Gastrotech Pharma A/S Utilisations de secretagogues

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AYALA ERNESTO RODRIGUEZ ET AL: "Associations between plasma ghrelin levels and body composition in end-stage renal disease: A longitudinal study.", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 19, no. 2, February 2004 (2004-02-01), pages 421 - 426, XP002390261, ISSN: 0931-0509 *
DJUKANOVIC LJUBICA ET AL: "Co-morbidity and kidney graft failure: Two main causes of malnutrition in kidney transplant patients.", NEPHROLOGY DIALYSIS TRANSPLANTATION, vol. 18, no. Supplement 5, July 2003 (2003-07-01), pages v68 - v70, XP002379509, ISSN: 0931-0509 *
JARKOVSKA Z ET AL: "Plasma ghrelin levels in patients with end-stage renal disease", PHYSIOLOGICAL RESEARCH, vol. 54, no. 4, 2005, pages 403 - 408, XP002390262, ISSN: 0862-8408 *
KALAITZAKIS EVANGELOS ET AL: "Altered postprandial leptin and ghrelin levels in liver cirrhosis: Correlations with energy intake and resting energy expenditure", HEPATOLOGY, vol. 42, no. 4, Suppl. 1, October 2005 (2005-10-01), & 56TH ANNUAL MEETING OF THE AMERICAN-ASSOCIATION-FOR-THE-STUDY-OF-LIVE R-DISEASES; SAN FRANCISCO, CA, USA; NOVEMBER 11 -15, 2005, pages 541, XP008063915, ISSN: 0270-9139 *
LAVIANO ALESSANDRO ET AL: "Therapy insight: Cancer anorexia-cachexia syndrome--when all you can eat is yourself.", NATURE CLINICAL PRACTICE. ONCOLOGY. MAR 2005, vol. 2, no. 3, March 2005 (2005-03-01), pages 158 - 165, XP002379780, ISSN: 1743-4254 *
MARCHESINI GIULIO ET AL: "Plasma ghrelin concentrations, food intake, and anorexia in liver failure", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, no. 5, May 2004 (2004-05-01), pages 2136 - 2141, XP002379681, ISSN: 0021-972X *
MURATA MASAHIRO ET AL: "Ghrelin modulates the downstream molecules of insulin signaling in hepatoma cells", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 277, no. 7, 15 February 2002 (2002-02-15), pages 5667 - 5674, XP002295567, ISSN: 0021-9258 *
NEARY NICOLA M ET AL: "Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial", JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, vol. 89, no. 6, June 2004 (2004-06-01), pages 2832 - 2836, XP002379511, ISSN: 0021-972X *
NISHIMATSU HIROAKI ET AL: "Ghrelin improves endothelial function in mice with ischemic acute renal failure.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 14, no. Abstracts Issue, November 2003 (2003-11-01), & MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY RENAL WEEK; SAN DIEGO, CA, USA; NOVEMBER 12-17, 2003, pages 325A, XP008066604, ISSN: 1046-6673 *
TACKE FRANK ET AL: "Ghrelin in chronic liver disease.", JOURNAL OF HEPATOLOGY, vol. 38, no. 4, April 2003 (2003-04-01), pages 447 - 454, XP002980898, ISSN: 0168-8278 *
TAKEDA R ET AL: "Ghrelin improves renal function in mice with ischemic acute renal failure", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 2006 UNITED STATES, vol. 17, no. 1, 2006, pages 113 - 121, XP008066603, ISSN: 1046-6673 *
TAKEDA RYO ET AL: "Ghrelin improves endothelial function of acute ischemic renal failure via insulin-like growth factor-1 signaling pathway", CIRCULATION, vol. 110, no. 17, Suppl. S, October 2004 (2004-10-01), & 77TH SCIENTIFIC MEETING OF THE AMERICAN-HEART-ASSOCIATION; NEW ORLEANS, LA, USA; NOVEMBER 07 -10, 2004, pages 231, XP008066608, ISSN: 0009-7322 *
WREN A M ET AL: "GHRELIN ENHANCES APPETITE AND INCREASES FOOD INTAKE IN HUMANS", JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, NEW YORK, NY, US, vol. 86, no. 12, December 2001 (2001-12-01), pages 5992 - 5995, XP001156529, ISSN: 0021-972X *
WYNNE KATIE ET AL: "Subcutaneous ghrelin enhances acute food intake in malnourished patients who receive maintenance peritoneal dialysis: A randomized, placebo-controlled trial", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 16, no. 7, July 2005 (2005-07-01), pages 2111 - 2118, XP008063751, ISSN: 1046-6673 *
YOSHIMOTO AKIHIRO ET AL: "Plasma ghrelin and desacyl ghrelin concentrations in renal failure", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 13, no. 11, November 2002 (2002-11-01), pages 2748 - 2752, XP002390260, ISSN: 1046-6673 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7851448B2 (en) 2004-11-24 2010-12-14 Neopro Labs, Llc Methods for modulating activities in plants
US7858586B2 (en) 2004-11-24 2010-12-28 Neopro Labs, Llc Method of treating condition in animal
US8492159B2 (en) 2004-11-24 2013-07-23 Neopro Pain, Inc. Methods and compositions for treating conditions
US8530432B2 (en) 2004-11-24 2013-09-10 Neopro Labs, Llc Methods and compositions for treating conditions
US8217141B2 (en) 2007-05-17 2012-07-10 Neopro Labs, Llc Crystalline and amorphous forms of peptide

Also Published As

Publication number Publication date
WO2006045319A2 (fr) 2006-05-04
EP1812044A2 (fr) 2007-08-01

Similar Documents

Publication Publication Date Title
WO2006045319A3 (fr) Utilisations de secretagogues d'hormones de croissance dans le traitement d'individus souffrant d'insuffisance renale et/ou hepatique
EP1504778A3 (fr) Pompe implantable pour le traitement de l'obésité
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
WO2005067898A3 (fr) Compositions a liberation prolongee amelioree pour la delivrance de proteines pharmaceutiques
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
WO2007117509A8 (fr) Vitesses d'administration élevées pour préparations médicamenteuses lipidiques et méthodes de traitement associées
BRPI0608271A2 (pt) controle superior de glicose no sangue em tratamento de diabette
EP2770853B1 (fr) Produit dietetique destine a la prevention du risque cardiometabolique
WO2002070438A3 (fr) Compositions permettant l'administration de biophosphonates
WO2004089336A3 (fr) Systemes d'administration de medicaments contenant un principe actif mis en gelule
EP2371853A3 (fr) Dérivés d'insuline ou ses sels pharmaceutiquement acceptables, composition pharmaceutique, utilisation du dérivé d'insuline et son sel pharmaceutiquement acceptable et procédé de traitement
WO2003079991A3 (fr) Technique d'administration d'hormone de croissance par voie pulmonaire
EP2497466A3 (fr) Préparation pour administration orale
WO2005097173A3 (fr) Utilisation d'un secretagogue pour le traitement d'une insuffisance en ghreline
AU2003207417A1 (en) Use of tryptophan rich peptides
WO2005044187A3 (fr) Preparations pharmaceutiques inhalables employant de l'anhydrate de lactose, et methodes d'administration desdites preparations
WO2005107810A3 (fr) Formulations pharmaceutiques et leurs utilisations dans le traitement du dysfonctionnement sexuel chez la femme
WO2007133796A3 (fr) Procédés et compositions de traitement de l'apnée du sommeil
WO2005027936A3 (fr) Traitement au moyen d'oligo-beta-(1,3)- glucanes et medicament utilises dans le cadre de ce traitement
WO2007038506A3 (fr) Methode de traitement de la cachexie
WO2006045314A3 (fr) Utilisation d'un secretagogue de l'hormone de croissance en vue d'accroitre ou de maintenir la masse maigre et/ou pour le traitement de la maladie pulmonaire obstructive chronique
WO2006045313A3 (fr) Utilisations de secretagogues pour le traitement de patients ayant subi une greffe d'organe
WO2005056520A8 (fr) Composes actifs du sous-type 1 de recepteur de somatostatine (sstr1) et leur utilisation en therapie
WO2002081521A8 (fr) Osteoprotegerine dans le lait
WO2008076296A3 (fr) Méthode améliorant la fonction de ventilation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MD MG MK MN MW MX MZ NA NG NO NZ OM PG PH PL PT RO RU SC SD SG SK SL SM SY TJ TM TN TR TT TZ UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005796707

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005796707

Country of ref document: EP